1246072-89-8 Usage
Molecular Structure
The compound consists of a benzo[b]thiophene ring, an acetamido group, and a thiophene-3-carboxamide group.
Functional Groups
The compound contains various functional groups, including an amide group and a carboxyamide group.
Thiophene Family
The compound is a member of the thiophene family, which is a group of organic compounds that contain a five-membered ring with one sulfur atom.
Potential Applications
The compound has potential in pharmaceutical and chemical applications, particularly in drug development, organic synthesis, and medicinal chemistry.
Unique Structure
The compound has a unique structure that may contribute to its potential reactivity and potential applications.
Further Research
More research and testing are needed to fully understand the properties and potential applications of 2-(2-(benzo[b]thiophen-3-yl)acetamido)thiophene-3-carboxamide.
Check Digit Verification of cas no
The CAS Registry Mumber 1246072-89-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,6,0,7 and 2 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1246072-89:
(9*1)+(8*2)+(7*4)+(6*6)+(5*0)+(4*7)+(3*2)+(2*8)+(1*9)=148
148 % 10 = 8
So 1246072-89-8 is a valid CAS Registry Number.
1246072-89-8Relevant academic research and scientific papers
Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase
De, Surya K.,Barile, Elisa,Chen, Vida,Stebbins, John L.,Cellitti, Jason F.,MacHleidt, Thomas,Carlson, Coby B.,Yang, Li,Dahl, Russell,Pellecchia, Maurizio
supporting information; experimental part, p. 2582 - 2588 (2011/05/17)
We report comprehensive structure-activity relationship studies on a novel series of c-Jun N-terminal kinase (JNK) inhibitors. Intriguingly, the compounds have a dual inhibitory activity by functioning as both ATP and JIP mimetics, possibly by binding to both the ATP binding site and to the docking site of the kinase. Several of such novel compounds display potent JNK inhibitory profiles both in vitro and in cell.
